Laekna, Inc. (HKG:2105)

Hong Kong · Delayed Price · Currency is HKD

6.05

+0.65 (12.04%)

Jul 31, 2026, 4:08 PM HKT

-68.42% (1Y)

Market Cap	2.56B -65.3%
Revenue (ttm)	118.76M
Net Income	-255.19M
EPS	-0.66
Shares Out	423.42M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,675,652
Open	5.48
Previous Close	5.40
Day's Range	5.48 - 6.05
52-Week Range	5.37 - 20.32
Beta	-1.00
Analysts	Strong Buy
Price Target	24.89 (+311.41%)
Earnings Date	Aug 14, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative brea... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 83

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2105

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 2105 stock is "Strong Buy." The 12-month stock price target is $24.89, which is an increase of 311.41% from the latest price.

Price Target

$24.89

(311.41% upside)

Analyst Consensus: Strong Buy

Stock Forecasts